Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

This is a phase 3b, controlled, open-label, multi-center study to evaluate safety and
immunogenicity of Menveo after a single vaccination in healthy individuals who were
vaccinated with Menveo or Menactra 4 to 6 years before and in vaccine-naive individuals.
Vaccine-naive subjects: subjects who have not received any meningococcal vaccine prior to
participation to this clinical trial.

Subjects will be randomised into one of the two different blood draw schedules according to a
1:1 ratio.

- Blood draws at Day 1, Day 4 and Day 29

- Blood draws at Day 1, Day 6 and Day 29

Inclusion Criteria:

1. Individuals of 15 through 55 years of age on the day of informed consent or assent.

2. Individuals who received Menveo 4 to 6 years prior to enrolment at an age of 11 years
or older OR Individuals who received Menactra 4 to 6 years prior to enrolment at an
age of 11 years or older OR Individuals who have not received any previous
meningococcal vaccine.

3. Individuals who have voluntarily given written informed consent after the nature of
the study has been explained according to local regulatory requirements, prior to
study entry. If the subject is under age 18 at the time of enrolment, the
parent(s)/legal guardian(s) of the subject should have voluntarily given written
informed consent.

4. Individuals who can comply with study procedures including follow-up.

5. Males Or Females of non-childbearing potential Or

- Females of childbearing potential who are using an effective birth control method
which they intend to use for at least 30 days after the study vaccination.

Exclusion Criteria:

Each subject must not have:

1. History of any meningococcal vaccine administration other than the single vaccination
given 4 to 6 years before OR History of any meningococcal vaccine administration.

2. Current or previous, confirmed or suspected disease caused by N. meningitidis.

3. Household contact with and/or intimate exposure to an individual with any laboratory
confirmed N. meningitidis infection within 60 days prior to study vaccination.

4. Progressive, unstable or uncontrolled clinical conditions.

5. Hypersensitivity, including allergy, to any component of vaccines, medicinal products
or medical equipment whose use is foreseen in this study.

6. Clinical conditions representing a contraindication to intramuscular vaccination (IM)
and blood draws.

7. Abnormal function of the immune system resulting from:

1. Clinical conditions.

2. Systemic administration of corticosteroids for more than 14 consecutive days
within 90 days prior to study vaccination.

3. Administration of antineoplastic and immunomodulating agents or radiotherapy
within 90 days prior to study vaccination.

8. Received immunoglobulins or any blood products within 180 days prior to informed
consent.

9. Received systemic antibiotic treatment within 3 days prior to study vaccination or
blood draw.

10. Received an investigational or non-registered medicinal product within 30 days prior
to study vaccination.

11. Study personnel as an immediate family or household member.

12. Individuals who have received any other vaccines within 7 days or 14 days prior to
vaccination in this study or who are planning to receive any vaccine within 28 days
from the study vaccination.

13. Individuals who have experienced a moderate or severe acute infection and/or fever
defined as a temperature ≥38°C (100.4°F) within 3 days prior to study vaccination.

14. Any other clinical condition that, in the opinion of the investigator, might pose
additional risk to the subject due to participation in the study.